BriaCell Therapeutics Corp. products

The mechanism of action of Bria-IMT™/Bria-OTS™ is currently under investigation. We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that Bria-IMT™/Bria-OTS™, exert their action by stimulating the antigen-presentation system (i.e. the system that presents antigen material on the surface of the tumor cells) – to be recognized by the T cells of the immune system.

We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type. We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, allowing for matching of over 99% of patients with advanced breast cancer. A simple saliva test is used to determine the HLA-type of each patient.

Early-Stage Preclinical Program: 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways. BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against multiple RAS transformed tumors. This target has an attractive safety profile based on in vivo studies and knock out mouse studies. PKCδ also has potential activity as an immunotherapeutic by blocking TGFβ signaling. PKCδ inhibitors are applicable to specific niche tumor types which provide an accelerated clinical development plan. Could be in clinic within 24 months. Provides Cost-Effective Additional Shot-on-Goal and additional partnership opportunities.

Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer fighting cells to attack and destroy breast cancer tumors.